Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2024	Mar. 31, 2023	Dec. 31, 2023
Cash flows from operating activities
Net loss	$ (4,649,635)	$ (4,477,778)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	6,568	5,043	$ 177,398
Stock-based compensation expense	53,434	123,273
Changes in operating assets and liabilities:
Accounts receivable	0	(24,638)
Operating lease right of use assets	28,767	25,380
Prepaid expenses and other current assets	(14,719)	(759,312)
Prepaid research and development	12,395	194,488
Accounts payable	479,267	(192,095)
Operating lease liabilities	(30,729)	(26,276)
Accrued expenses and other current liabilities	247,634	(840,215)
Net cash used in operating activities	(3,867,018)	(5,972,130)
Cash flows from investing activities
Purchases of investments - marketable securities	(8,432,571)	(21,611,032)
Maturities of investments - marketable securities	5,120,757	15,772,190
Net cash used in investing activities	(3,311,814)	(5,838,842)
Cash flows from financing activities
Deferred offering costs	(30,608)	0
Proceeds from issuance of common stock, pre-funded warrants and warrants, net of issuance costs	397,607	8,579,023
Net cash provided by financing activities	366,999	8,579,023
Net decrease in cash and cash equivalents	(6,811,833)	(3,231,949)
Cash and cash equivalents at beginning of year	9,165,179	7,188,553	7,188,553
Cash and cash equivalents at end of year	2,353,346	3,956,604	$ 9,165,179
Supplemental disclosures of cash flow information
Issuance costs	407,329	1,420,398
Non cash financing activities
Deferred offering costs	$ 167,721	$ 0